713c3ad2-c1d0-45ed-b69e-f6cedd57933a
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 63
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.420
- OXIDATIVE_PHOSPHORYLATION+0.380
- GLYCOLYSIS+0.320
- PANCREAS_BETA_CELLS+0.310
- INTERFERON_ALPHA_RESPONSE+0.290
- FATTY_ACID_METABOLISM+0.260
- APICAL_SURFACE+0.240
- ESTROGEN_RESPONSE_EARLY+0.240
- ANGIOGENESIS+0.220
- ADIPOGENESIS+0.210
Top 10 suppressed
- MYC_TARGETS_V2-0.320
- WNT_BETA_CATENIN_SIGNALING-0.260
- E2F_TARGETS-0.180
- INFLAMMATORY_RESPONSE-0.140
- G2M_CHECKPOINT-0.110
- NOTCH_SIGNALING-0.090
- ALLOGRAFT_REJECTION-0.080
- HEDGEHOG_SIGNALING-0.080
- BILE_ACID_METABOLISM-0.060
- IL6_JAK_STAT3_SIGNALING-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313114 | — | B | 0.723 |
| 2 | SRR8518232 | — | C | 0.691 |
| 3 | DRR168524 | — | — | 0.689 |
| 4 | TCGA-78-7148-01A-11R-2039-07 | — | cohortA4 | 0.677 |
| 5 | TCGA-A2-A0CS-01A-11R-A115-07 | — | C | 0.667 |
| 6 | MNG554 | — | — | 0.666 |
| 7 | SRR33346941 | — | — | 0.663 |
| 8 | BS_M026T44Q | Meningioma | — | 0.653 |
| 9 | e5ae4a47-9a0d-4a70-a7be-40bddeb3d017 | — | — | 0.651 |
| 10 | SRR35579816 | — | C | 0.644 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |